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The fibroblast growth factor–receptor 3 (FGFR3) Lys650 codon is located within a critical region of the tyrosine
kinase–domain activation loop. Two missense mutations in this codon are known to result in strong constitutive
activation of the FGFR3 tyrosine kinase and cause three different skeletal dysplasia syndromes—thanatophoric
dysplasia type II (TD2) (A1948G [Lys650Glu]) and SADDAN (severe achondroplasia with developmental delay
and acanthosis nigricans) syndrome and thanatophoric dysplasia type I (TD1) (both due to A1949T [Lys650Met]).
Other mutations within the FGFR3 tyrosine kinase domain (e.g., C1620A or C1620G [both resulting in Asn540Lys])
are known to cause hypochondroplasia, a relatively common but milder skeletal dysplasia. In 90 individuals with
suspected clinical diagnoses of hypochondroplasia who do not have Asn540Lys mutations, we screened for mu-
tations, in FGFR3 exon 15, that would disrupt a unique BbsI restriction site that includes the Lys650 codon. We
report here the discovery of three novel mutations (G1950T and G1950C [both resulting in Lys650Asn] andA1948C
[Lys650Gln]) occurring in six individuals from five families. Several physical and radiological features of these
individuals were significantly milder than those in individuals with the Asn540Lys mutations. The Lys650Asn/Gln
mutations result in constitutive activation of the FGFR3 tyrosine kinase but to a lesser degree than that observed
with the Lys540Glu and Lys650Met mutations. These results demonstrate that different amino acid substitutions
at the FGFR3 Lys650 codon can result in several different skeletal dysplasia phenotypes.
Introduction
Hypochondroplasia (MIM 146000) is an autosomal
dominant skeletal dysplasia that was probably first de-
scribed by Ravenna (1913) but not generally recognized
until much later, the term being coined by Maroteaux
and Lamy (1960). Although many reports characteriz-
ing the phenotypic features have since appeared in the
literature (Kozlowski 1965; Beals 1969; Walker et al.
1971; Hall and Spranger 1979; Wynne-Davies et al.
1981; Maroteaux and Falzon 1988), it is sometimes dif-
ficult to make a definitive diagnosis of hypochondro-
plasia solely on the basis of physical and radiological
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findings, especially in young children and milder cases.
Hypochondroplasia and achondroplasia share many
phenotypic features (e.g., apparent rhizomelia, limita-
tion of elbow extension, tibial bowing, exaggerated lum-
bar lordosis, metaphyseal flaring, shortening of the ped-
icles, narrowing of the lumbar interpediculate distance,
squared ilia, shortened femoral necks, brachydactyly,
macrocephaly, and distinctive facial features). However,
in hypochondroplasia these features tend to be milder,
and some are often subtle or absent in any given indi-
vidual. For these reasons, the diagnosis is frequently not
made until later in childhood, when growth delay is first
noted; and, consequently, reliable data about the inci-
dence and prevalence of hypochondroplasia have not
been compiled.
McKusick et al. (1973) first proposed that achondro-
plasia and hypochondroplasia are allelic disorders, on
the basis of both the similarity of the clinical and ra-
diological features and their analysis of a hypochon-
droplasia/achondroplasia compound heterozygote. This
hypothesis was confirmed later, with the discovery of
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Figure 1 BbsI digestion and DNA sequencing of FGFR3 exon
15 PCR products. A, BbsI digestion of exon 15 PCR products for four
families. The mutant allele is not digested in affected individuals.Lane
M, 100-bp DNA-ladder standard. B, Automated DNA sequencing,
which reveals the presence of a heterozygous G1950C/K650N mu-
tation in patient 1 (top) and a heterozygous G1950T/K650N in patient
4 (middle). Patients 2, 3, and 6 were also found to have G1950C/
K650N mutations (data not shown). Control sequence (bottom) is
depicted with theBbsI restriction site underlined. Sequencing autora-
diography of patient 5 (left gel) shows the presence of a heterozygous
A1948C/K650Q mutation (arrow) not seen in the control (right gel).
distinctive mutations, for each disorder, in the fibroblast
growth factor–receptor 3 (FGFR3) gene located on hu-
man chromosome 4 (4p16.3). Two recurrent mutations
in exon 10 (G1138A and G1138C [both resulting in
Gly380Arg]) account for 99% of all cases of achon-
droplasia (Shiang et al. 1994; Rousseau et al. 1994;
Bellus et al. 1995a), and two recurrent mutations in
exon 13 (C1620A and C1620G [both resulting in
Asn540Lys]) account for ∼50%–70% of all cases of
hypochondroplasia (Bellus et al. 1995b, 1996; Prinos
et al. 1995; Prinster et al. 1998; Ramaswami et al. 1998;
Grigelioniene et al. 2000). The etiology of the hypo-
chondroplasia phenotype in most of the remaining in-
dividuals remains unknown. Genetic-locus heteroge-
neity has been established in a few multiplex families
with exclusion of linkage to 4p16.3 (Stoilov et al. 1995;
Rousseau et al. 1996; Grigelioniene et al. 2000). In ad-
dition, several other FGFR3 mutations have been re-
ported recently in isolated families (Ile538Val [Grige-
lioniene et al. 1998], Asn540Thr [Deutz-Terlouw et
al. 1998], Asn328Ile [Winterpacht et al. 2000], and
Asn540Ser [Mortier et al. 2000]).
Given that there are now at least two different types
of hypochondroplasia (those with known FGFR3 mu-
tations and those without), attempts have been made
to identify phenotypic differences between these two
groups (Rousseau et al. 1996; Prinster et al. 1998; Ra-
maswami et al. 1998; Grigelioniene et al. 2000). These
studies have demonstrated that patients with FGFR3
Asn540Lys mutations tend to be more disproportion-
ate, have larger heads and shorter hands, and tend to
exhibit more of the characteristic radiological findings
than are seen in patients without the FGFR3 Asn540Lys
mutation. We have been screening selected areas of the
FGFR3 coding region for new point mutations in pa-
tients with suspected diagnoses of hypochondropla-
sia who do not have the FGFR3 Asn540Lys mutation.
We report here the discovery of three novel FGFR3
mutations (G1950T and G1950C [both resulting in
Lys650Asn] and A1948C [Lys650Gln]) occurring in six
individuals from five families. A quantitative analysis
of selected physical and radiological features of these
individuals reveals that they have a milder phenotype
than that seen in patients with the FGFR3 Asn540Lys
mutation. We also demonstrate that the Lys650Asn/Gln
mutations result in constitutive activation of the FGFR3
tyrosine kinase but to a lesser degree than is seen in
TD2 (thanatophoric dysplasia type II) Lys650Glu mu-
tations and in SADDAN (severe achondroplasia with
developmental delay and acanthosis nigricans) syn-
drome/TD1 (thanatophoric dysplasia type I) Lys650Met
mutations (Kitoh et al. 1998; Tavormina et al. 1999).
Patients and Methods
Recruitment of Patients
Patients were recruited by several of the authors and
other collaborating physicians. All patients in whom a
diagnosis of hypochondroplasia was considered possible
by the referring physician were eligible to be included
in the study. Blood samples and clinical data were ob-
tained after patients or their parents gave informed con-
sent. The protocol was approved by the institutional-
review-board committees at the University of Colorado
and the National Institutes of Health.
Clinical Data
The referring physicians collected clinical and auxo-
logical data, and copies of radiographs from all patients
with FGFR3 Lys650Asn/Gln mutations were analyzed
by one of the authors (G.A.B.). Metacarpophalangeal
profiles (MCPs) were generated on the basis of hand
radiographs, according to the method of Poznanski
(1984). Quantification of other radiological parame-
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Figure 2 Photographs of patients. Note the mild shortening of the arms and normal facial appearance in patient 1, who has G1950C
(Lys650Asn) and is shown at age 15 years (A–D), whereas patient 4, who has G1950T (Lys650Asn) and is shown at age 15 mo (E and F),
and patient 5, who has A1948C (Lys650Gln) and is shown at age 20 mo (G), have more-prominent dysmorphic facial features.
ters (pelvic index, fibula:tibia length ratio, and L1:L4
interpediculate-distance ratio) was performed according
to the method of Matsui et al. (1998). SDs (Z scores)
for height and head circumference were calculated from
standard growth charts. The two-tailed t-test (Glantz
1997) was used to compare data from patients with
either Asn540Lys or Lys650Asn/Gln mutations.
Case Summaries
Family 1: patient 1 (G1950C [Lys650Asn]).—This girl
was the product of a normal pregnancy, labor, and de-
livery to average-stature parents (mother, 166 cm; father,
178 cm). Her growth was uneventful until age 3.5 years,
when it slowed substantially and did not increase for 12
mo. She was evaluated at age 5 years, for short stature.
Her height at age 5 years was 97.4 cm (!3d percentile
for age 5 years/50th percentile for age 3.5 years), and
her head circumference was 195th percentile. Her phys-
ical examination revealed mild frontal bossing, tibial
bowing, and some limitation of elbow extension. A skel-
etal survey was obtained but was not considered to be
diagnostic of any skeletal dysplasia. Results of thyroid
studies were normal, but bone age showed discrepancy
between hand bones (4.5 years) and wrist bones (2.5
years). Karyotype and levels of alkaline phosphatase,
calcium, and phosphorus were normal. Cognitive, ver-
bal, and social development were appropriate for age.
The patient’s growth velocity has decreased slightly with
time, and at age 15 years 5 mo her height was 141.9
cm (!3d percentile for age 15 years 5 mo/50th percentile
for age 10.5 years), and head circumference was 56 cm
(∼95th percentile).
Family 2: patient 2 and patient 3 (G1950C
[Lys650Asn]).—The girl in family 2 (patient 2) was the
product of a normal pregnancy. Growth was reported
to be normal during the 1st year of life but then slowed
by age 18 mo. She was evaluated for short stature at
age 2 years, and no specific causes of growth delay were
found. She has had no other significant medical prob-
lems, and her development has been completely appro-
priate. Growth velocity has remained relatively constant.
At age 5 years, the patient’s height was 96.2 cm (!3d
percentile for age 5 years/50th percentile for age 3 years
6 mo), and her head circumference measured 50.5 cm
(50th percentile). She has mild lumbar lordosis and nor-
mal alignment of her lower legs. Upper extremities show
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Figure 3 Radiographs of patients. The skull radiograph of patient 4 at age 15 mo (A) exhibits macrocephaly and frontal bossing, whereas
that of patient 6 at age 2 years (B) is less disproportionate. AP spines of patient 3 at age 39 years (C) and of patient 5 at age 18 mo (E) show
some widening of the interpediculate distances (i.e., width of the spinal canal), proceeding from L1 to L4, although this is less than normal.
Shortening of the lumbar pedicles as seen in the lateral spine views (i.e., depth of spinal canal) is observed in patient 3 at age 39 years (D) but
is less severe in patient 5 at age 18 mo (F). The pelvis of patient 4 at age 15 mo (G) is relatively normal, except for shortened femoral necks,
whereas patient 5 at age 18 mo (H) shows shortening of the femoral necks and narrowing of the greater sciatic notch.
full range of motion, and the patient has normal-ap-
pearing hands and feet. The parents’ heights are rela-
tively short (mother, 152 cm; father, 163 cm).
This girl’s father (patient 3) has a history of spon-
dylolisthesis and knee pain. His height is shorter than
would be expected on the basis of his parents’ height
(mother, 157.5 cm; father, 183 cm), and his upper:lower
segment ratio is 1.14 (12 SD), indicating disproportion-
ately short legs. His head circumference is large, mea-
suring 60.8 cm (198th percentile).
Family 3: patient 4 (G1950T [Lys650Asn]).—This girl
was born at 36 wk gestation, after a twin pregnancy
complicated by late preeclampsia. Delivery was by ces-
arean section; birth weight was 2,894 g (75th percentile),
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Figure 4 Radiographs and photographs of extremities. In patient
3 at age 39 years (A), patient 1 at age 13 years (B), and patient 4 at
age 15 mo (C), the fibula:tibia length ratio is close to normal. There
is moderately exaggerated flaring of the distal femoral and proximal
tibial metaphyses in the younger patient (C). There is mild to moderate
shortening of the metacarpals and phalanges in patient 1 at age 15
years (D and F), which is more pronounced in patient 4 at age 15 mo
E and G).
and birth length was 48.3 cm (75th percentile). Accel-
eration of head-circumference growth was noted at age
3 wk. Linear growth was tracking between the 30th and
50th percentiles until age 1 year and then dropped to
the 10th percentile. Head circumference, which had been
at the 75th percentile, increased to 12 SD above the 95th
percentile by age 15 mo. Developmental progress has
been appropriate, although she has been noted to lag
1–2 mo behind her fraternal twin. Parental heights are
low average (mother, 155 cm; father, 173 cm), and the
patient’s fraternal twin is at the 30th–35th percentiles
for height and weight. Physical examination at age 15
mo was significant for a height of 73.5 cm (10th per-
centile) and occipitofrontal circumference (OFC) of 51.3
cm (12 SD above 95th percentile). There was significant
frontal bossing but no evidence of craniosynostosis. The
patient had subtle epicanthal folds, a flattened nasal
bridge, noticeable lumbar lordosis, subtle rhizomelia,
and tibial bowing. Her hands were small, with significant
shortening of the phalanges and a “trident” appearance.
She had full range of motion at all joints and extra folds
of skin on the thighs and upper arms.
Family 4: patient 5 (A1948C [Lys650Gln]).—This boy
was born vaginally at 35 wk gestation. Results of pre-
natal ultrasonography at 18 wk gestation showed larger
than expected head size, and repeat ultrasounds at 26
and 31 wk gestation revealed shorter than expected ex-
tremities. DNA testing for achondroplasia was offered
to the patient’s parents but was declined. Birth weight,
length, and head circumference were all between the
75th and 90th percentiles. At age 15 mo, the patient
was evaluated for progressive macrocephaly and had a
normal head CT. Hearing and vision are normal, but
the patient is thought to have mild delays in motor and
speech/language development. At age 18 mo he was re-
ferred for genetic evaluation. The parents’ heights are
average to tall (mother, 168 cm; father, 183 cm). At age
18 mo, the patient’s height was 78.1 cm (10th percen-
tile), and his OFC was 53 cm (195th percentile for age
18 mo/50th percentile for age 10 years). He was noted
to have a scaphocephalic head with a large open anteri-
or fontanelle, frontal bossing, mildly depressed nasal
bridge, mild shortening of upper and lower extremities
with full range of motion, relatively short hands with
bilateral single palmar crease, and mild hypotonia.
Family 5: patient 6 (G1950C [Lys650Asn]).—This
boy’s birth weight and length were 4.029 kg and 58.4
cm, respectively. No problems were noted until age 9
mo, when tibial bowing was detected. The patient began
walking at age 11 mo, and his tibial bowing increased
in severity. Orthopedic and genetic evaluations were per-
formed at age 2 years. Physical examination was notable
for a height of 87.6 cm (25th–50th percentile) and head
circumference of 52.5 cm (195th percentile). The fore-
head was slightly prominent but did not have fron-
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Figure 5 MCP. The lengths of the metacarpals and phalanges were measured on the basis of radiographs of the hands of each patient,
and Z scores were determined according to the method of Poznanski (1984); the average Z score for each metacarpal (mc1–mc5) and phalanx
(pp1–pp5, mp2–mp5, and dp1–dp5) is shown.  p FGFR3 Lys650Asn/Gln ( );  p FGFR3 Asn540Lys ( ) (Prinster et al. 1998);np 6 np 9
 p radiologically confirmed hypochondroplasia ( ) (Hall and Spranger 1979). The range in Z scores for each bone is shown for thenp 21
patients with Lys650Asn/Gln mutations.
tal bossing. Levels of calcium, phosphorus, parathyroid
hormone, 1-25 vitamin D, and alkaline phosphatase
were normal, and x-rays of the lower extremities were
suggestive of achondroplasia/hypochondroplasia with
widening of the proximal tibial and distal femoral me-
taphyses and narrow greater sciatic notches. The par-
ent’s heights are tall to average (mother, 180.3 cm; fa-
ther, 176.5 cm). Both parental head circumferences
exceeded the mean by 12 SD deviations.
Mutation Analysis
Genomic DNA was isolated from blood samples by
established methods (Bellus et al. 1995a). PCR ampli-
fication of FGFR3 exons 10, 13, and 15 were performed
as described elsewhere (Bellus et al. 1995a, 1995b; Ta-
vormina et al. 1995). Screening for Gly380Arg muta-
tions in exon 10 was performed by digestion with re-
striction enzymes SfcI and MspI. Screening for exon 13
Asn540Lys mutations was performed by digestion with
restriction enzymes AluI and BspMI (Bellus et al. 1996;
Prinster et al. 1998), and screening for mutations in exon
15 codons 649–651 was performed by digestion with
restriction enzyme BbsI (Tavormina et al. 1995). Prod-
ucts of restriction-enzyme digestion were analyzed by
agarose gel electrophoresis and were visualized by stain-
ing with ethidium bromide.
PCR products for sequencing of the Lys650Asn mu-
tations were generated by use of nested primers. The
forward nested primers were labeledwith fluoresceinCy-
5, and the reverse nested primers were labeled with Cy-
5.5. Sequencing was performed by the two-dye PCR Se-
quencing Reaction protocol provided by Visible Ge-
netics. The sequence of the PCR products was deter-
mined by the Long Read Tower System from Visible
Genetics. Sequencing of the Lys650Gln mutations was
performed by use of the gel-purified exon 15 PCR prod-
uct, with a nested sequencing primer, [32P]-dCTP, and a
Thermo Sequenase Cycle Sequencing kit (USB). Reaction
products were separated on a standard polyacrylamide
sequencing gel and were visualized by autoradiography.
FGFR3 Transfection and Autophosphorylation Studies
Point mutations in an FGFR3 cDNA construct were
created according to methods described elsewhere (Web-
ster et al. 1996) and were confirmed by sequencing.
Transfection, immunoprecipitation, and autophosphor-
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Figure 6 Autophosphorylation of FGFR3 cDNA mutant con-
structs. FGFR3 cDNA constructs comprising all of the possible amino
acid substitutions resulting from single nucleotide changes of the
Lys650 codon were synthesized and transfected into NIH 3T3 cells.
FGFR3 was immunoprecipitated from cell lysates and incubated with
[32P]-ATP in an autophosphorylation assay. Equal amounts of im-
munoprecipitate (lower panel) were then separated by gel electropho-
resis and were exposed to x-ray film. The locations ofmolecular-weight
markers (in kD) are shown on the left. The relative activity of the
mutations, compared with that in the wild type, was determined by
densitometry and is as follows: K650R, 1.5#; K650N, 3.7#; K650Q,
4.9#; K650T, 3.1#; K650E, 9.6#; and K650M, 18.1#.
Figure 7 FGFR3 hypochondroplasia mutations. A schematic of
the FGFR3 protein is shown, and the areas within the three exons
where hypochondroplasia missense mutations occur are shown in
greater detail. The nucleotide substitutions are shown above, and the
amino acid substitutions are shown below; for comparison, the mu-
tations causing TD2 and SADDAN syndrome are also shown.
ylation studies were performed as described elsewhere
(Webster et al. 1996; Tavormina et al. 1999).
Results
Loss of the FGFR3 Exon 15 BbsI Site
In an ongoing study, we have screened for FGFR3
mutations in 211 individuals with suspected diagnoses
of hypochondroplasia and have found that 110 (52.1%)
have Asn540Lys mutations (C1620A or C1620G). Of
the 101 individuals without Asn540Lys mutations, 11
(10.9%) were shown to have the common FGFR3
achondroplasia mutation (G1138A [Gly380Arg]). By di-
gestion with BbsI, we screened the remaining 90 indi-
viduals for alterations in FGFR3 exon 15, and we iden-
tified 6 individuals from five families who lost the BbsI
site on one allele. Loss of a unique BbsI restriction site
in exon 15 has been used to screen for FGFR3 A1948G
(Lys650Glu) and A1949T (Lys650Met)mutations found
in TD2 (Tavormina et al. 1995) and SADDAN syndrome
(Tavormina et al. 1999), respectively. The 6-bp recog-
nition sequence of BbsI spans codons 649–651, and loss
of this site will detect any missense mutation in codon
650, as well as any changes in both the last position of
codon 649 and the first two positions of codon 651.
Polymorphisms do not commonly occur within this se-
quence, since none were found in screening 1100 normal
chromosomes (Tavormina et al. 1995). In these six in-
dividuals, we determined that the loss of the BbsI site
occurred sporadically in three cases and cosegregated
with disproportionate and short stature in another fam-
ily (fig. 1A). Sequencing of the PCR products revealed
the presence of three novel mutations that result in
Lys650Asn substitutions (produced by both G1950C
and G1950T) and in Lys650Gln (A1948C) substitutions
(fig. 1B).
Quantitative Analysis of Auxological and Radiological
Data
On review of photographs (fig. 2) and medical re-
cords, it was our general impression that these patients
tended to have a milder hypochondroplasia phenotype
than we have seen in patients with Asn540Lys muta-
tions. To confirm this impression, a quantitative analy-
sis of auxological and radiological parameters was per-
formed. The auxological parameters were compared
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Table 1
Phenotypic Data for Patients with either Asn540Lys Mutations or Lys650Asn/Gln Mutations
MEAN  SD [NO. OF PATIENTS]
P bAsn540Lysa Lys650Asn/Gln
Auxological data:
Height (Z score) 3.25  1.09 [36] 1.87  .99 [6] !.02
Arm span:height .995  .17 [28] .982  .04 [5] NS
OFC (Z score) 1.72  1.11 [37] 2.48  1.65 [6] !.2
Radiological data:
L1:L4 interpediculate-distance ratio 1.02  .09 [8] .91  .07 [6] !.05
Fibula:tibia length ratio 1.07  .03 [8] 0.91  .07 [6] !.005
Pelvic index .37  .04 [8] .40  .02 [6] NS
a Data are from Matsui et al. (1998).
b NS p not significant.
with data that we have obtained from 38 individuals
with established FGFR3 Asn540Lys mutations. Quan-
tification of radiological data from our patients with
FGFR3 Lys650Asn/Gln mutations was performed ac-
cording to the method of Matsui et al. (1998), and com-
parison was made with their data set from eight pa-
tients with established Asn540Lys mutations. In ad-
dition, MCPs were determined for all individuals with
Lys650Asn/Gln mutations and were compared both
with Prinster et al.’s (1998) data from patients with
Asn540Lys mutations and with Hall and Spranger’s
(1979) data from patients with radiologically confirmed
diagnoses of hypochondroplasia.
As shown in table 1, patients with Lys650Asn/Gln
mutations have a statistically significant smaller height
deficit than is seen in patients with Asn540Lys muta-
tions ( [ ] vs. [SD pZp 1.87 SDp 0.99 Zp 3.25
1.09]; ). Disproportion of the upper extremitiesP ! .02
was similar in both groups, as indicated by the arm span:
height ratio. The degree of macrocephaly appeared to
be greater in the patients with Lys650Asn/Gln, but it
did not quite reach statistical significance. Narrowing of
the lumbar interpediculate distances was significantly
milder in patients with Lys650Asn/Gln mutations than
in patients with Asn540Lys mutations (fig. 3). Both
groups showed the typical exaggerated metaphyseal flar-
ing of the proximal tibiae, but disproportionate elon-
gation of the fibulae was significantly less in the patients
with Lys650Asn/Gln mutations (fig. 4). The pelvic index
was essentially normal in patients with Lys650Asn/Gln
and in patients with Asn540Lys mutations. Finally, the
MCP of patients with Lys650Asn/Gln mutations was
substantially different from that observed in patients
with Asn540Lys mutations and in patients with radio-
logically confirmed hypochondroplasia (figs. 4 and 5).
Although there is nearly equivalent shortening of the
distal phalanges in all three groups, the patients with
Lys650Asn/Gln exhibit generally less disproportion in
the metacarpals, proximal phalanges, and middle pha-
langes.
Lys650Asn/Gln: Constitutive Activation of FGFR3
Tyrosine Kinase
To compare the effect of the FGFR3 Lys650Asn mu-
tations (which were discovered prior to the Lys650Gln
mutations) with that of other FGFR3 mutations at co-
don 650, a series of FGFR3 cDNA constructs repre-
senting all of the possible amino acid substitutions re-
sulting from one-nucleotide substitutions in codon 650
were made. These mutant constructs were transiently
expressed in NIH 3T3 cells, and cell extracts were im-
munoprecipitated with an FGFR3 antibody. A [32P]-ATP
autophosphorylation assay was used to test the for con-
stitutive kinase activity in the immunoprecipitates, and
they were evaluated by gel electrophoresis. As shown in
figure 6, the Lys650Asn/Gln and Lys650Thr mutations
result in similar degrees of constitutive FGFR3 tyro-
sine kinase activation (approximately three- to fivefold
greater than that in the wild type). The activities of these
three mutations are considerably less than those of the
Lys650Glu and Lys650Met mutations that are associ-
ated with TD2 and SADDAN syndrome, and the latter
two mutations are, respectively, ∼10 and ∼18 times
greater than that of the wild type.
Discussion
We have discovered within the FGFR3 Lys650 codon
three new mutations that result in a mild hypochon-
droplasia phenotype. We now know of nine missense
mutations, which result in seven different amino acid
substitutions within four FGFR3 codons that cause hy-
pochondroplasia (fig. 7). The two mutations that result
in Asn540Lys substitutions remain, by far, themost com-
mon (52% in this study). However, the Lys650Asn/Gln
mutations that we have reported here are reasonably
common, being detected in 2.8% (6 of 211) of the total
number of patients screened and in 6.7% (6 of 90) of
patients without other known FGFR3 mutations. These
mutations may account for an even higher proportion
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of true cases of hypochondroplasia, since the inclusion
criteria for patients in this study were relatively relaxed
and other causes of short stature had not yet been com-
pletely eliminated in many of the patients in whom we
did not detect FGFR3 mutations.
The facts that these new FGFR3 mutations cause dif-
ferent amino acid substitutions within the same codon
that is affected in both TD2 and SADDAN syndrome
and result in lower levels of ligand-independent FGFR3
kinase activation further highlights the importance of
the Lys650 residue in the biological function of FGFR3.
Lys650 is located within the activation loop of the
FGFR3 tyrosine kinase domain (Mohammadi et al.
1996), and amino acid substitutions at this position
have been shown to have a dramatic effect on the con-
stitutive activation of FGFR3-mediated receptor auto-
phosphorylation (Webster et al. 1996; Tavormina et al.
1999). The activation loop of FGFRs is thought to block
substrate binding until FGF binding and receptor di-
merization alter its conformation, permitting both au-
tophosphorylation of the receptor and phosphoryla-
tion of intermediate signaling molecules (Mohammadi
et al. 1996). Webster et al. (1996) have shown that the
Lys650 codon plays a critical role in stabilizing the
FGFR3 activation loop in an inactive conformation,
since different mutations of this residue constitutively
activate the tyrosine kinase to varying degrees whereas
mutations of adjacent codons have little effect. In ad-
dition, mutations of this residue may preclude the need
for receptor dimerization at the cell membrane to ac-
tivate the tyrosine kinase. A similar construct of Xeno-
pus FGFR2 (Lys652Glu) is not inhibited by dominant-
negative FGFR constructs that competitively inhibit
receptor dimerization (Neilson and Freisel 1996). Raf-
fioni et al. (1998) have shown that chimeric PDGFR-
FGFR3 Lys650Glu and Lys650Met constructs ex-
pressed in PC12 cells produce only small amounts of
mature-size (i.e., glycosylated) receptor protein but ex-
hibit strong ligand-independent autophosphorylation of
a smaller, presumably intracellular, form of the receptor.
Our findings establish a clear correlation, in human
skeletal dysplasias, between the level of constitutive
FGFR3 tyrosine kinase activation due to different ami-
no acid substitutions at the Lys650 codon and the se-
verity of the disturbance in endochondrial ossification.
Although the overall TD2 phenotype is more severe
than that of SADDAN, and although, in our assay, the
Lys650Met mutations were more active than the
Lys650Glu mutations, dysplasia of the long bones is
generally more severe in SADDAN syndrome than in
TD2. These results add further support to the theory
that FGFR3 normally functions as a negative regulator
of bone growth and that FGFR3mutations causing skel-
etal dysplasias result in inappropriate activation of
FGFR3 signaling (Colvin et al. 1996; Deng et al. 1996;
Naski et al. 1996; Webster et al. 1996).
Aside from the skeletal findings, it is interesting that
the patients with Lys650Asn/Glu mutations do not ex-
hibit significant developmental delay or cognitive im-
pairments (although mild delays were suspected in pa-
tients 4 and 5), acanthosis nigricans, or craniosyn-
ostosis. Abnormal brain development is a feature of
TD1, TD2 (Ho et al. 1984), and SADDAN syndrome
(Bellus et al. 1999). Postnatal onset of acanthosis ni-
gricans occurs in SADDAN syndrome, in Crouzonoder-
matoskeletal syndrome (Ala391Glu mutations) (Meyers
et al. 1995), and in rare cases of TD1 (Arg248Cys mu-
tations) with prolonged survival (Baker et al. 1997). In
both TD2 and Crouzonodermatoskeletal syndrome,
craniosynostosis is frequently observed with acanthosis
nigricans. The reason why only some FGFR3 mutations
are strongly correlated with these phenotypic features
is not currently understood. It is likely that some amino
acid substitutions do more than modulate ligand-in-
dependent activation of the FGFR3 intracellular kinase
domain. Raffioni et al. (1998) have demonstrated that
PDGFR-FGFR3 chimeras with either Lys650Glu or
Lys650Met mutations vary considerably in their ability
to activate downstream signaling pathways and to in-
duce neurite outgrowth in PC12 cells, even though both
mutations result in comparable constitutive activation
of FGFR3 tyrosine kinase.
It is notable that we have found several phenotypic
differences between patients with FGFR3 Asn540Lys
mutations and those with FGFR3 Lys650Asn/Gln mu-
tations. The difference, in head circumference, between
individuals with Lys650Asn/Gln mutations and those
with Asn540Lys mutations was not statistically signif-
icant in this study, but it is interesting that two of our
patients came to medical attention primarily because
of progressive macrocephaly with head circumferences
that were significantly above the 95th percentile. Given
the severity of the craniofacial findings in both TD2 and
SADDAN syndrome, it seems possible that mutations
at this position may have a greater effect on craniofacial
growth than is seen for other FGFR3 mutations asso-
ciated with hypochondroplasia.
The observation that individuals with FGFR3
Lys650Asn/Gln mutations have milder radiological fea-
tures than are seen in individuals with Asn540Lys mu-
tations is also interesting. It is notable that, even though
complete skeletal surveys were obtained on all six pa-
tients with Lys650Asn/Gln mutations, a radiological di-
agnosis of hypochondroplasia versus achondroplasia
was made in only one patient (patient 6), whose height
was between the 25th and 50th percentiles. All the other
patients showed some features consistent with hypo-
chondroplasia, but these features were sufficiently mild
or few in number that this diagnosis could not be made
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with confidence. Limb disproportion is a common find-
ing among all types of hypochondroplasia. It is inter-
esting that, even though two patients with Lys650Asn
mutations were noted to have tibial bowing, the fibula:
tibia length ratios of the patients with Lys650Asn/Gln
mutations are significantly less disproportionate than
those in patients with the Asn540Lys mutations.
It is perhaps most surprising that patients with
Lys650Asn/Gln mutations were significantly taller than
patients with the Asn540Lys mutations. Even though
our one adult patient (patient 3) had significant skele-
tal disproportion, his height (163 cm) was sufficient to
prevent him from being perceived by his family or ac-
quaintances as having dwarfism. Parental heights can
influence the height of patients with skeletal dysplasias,
but abnormally great parental height does not account
for the decreased height deficit observed in our patients.
In our patients with Lys650Asn/Gln mutations, the av-
erage height of unaffected mothers is 163.1 cm (range
152–180 cm), and the average height of unaffected fa-
thers is 178.7 cm (range 173–183 cm), both of which
are near the 50th percentile. In the largest clinical series
on hypochondroplasia published to date, Maroteaux
and Falzon (1988) reported the average height of adult
men to be 146 cm (4.98 cm), with their tallest patient
being 153 cm. Molecular diagnosis was not available
at that time, but it is safe to assume that their patients
represented a mixture of individuals with and without
the FGFR3 Asn540Lys mutation. Our six adult patients
with Asn540Lys mutations ranged in height from 128
cm to 142.2 cm. It is notable that some adult patients
with either FGFR3 Ile538Val mutations (Grigelioniene
et al. 1998) or FGFR3 Asn540Ser mutations (Winter-
pacht et al. 2000) were also relatively tall, with maxi-
mum heights of ∼157 cm in women and 167.9 cm in
men, which are, respectively, 1 SD and 1.3 SD from
the mean.
Together, these results support the prediction by Ri-
moin (1975) that individuals with mild forms of hy-
pochondroplasia would blend in with individuals on the
shorter end of the normal height spectrum and would
not necessarily come to medical attention. Given both
the relatively high rate of missense mutations in the
FGFR3 gene (Bellus et al. 1995a) and the fact that, in
terms of free energy, there is probably a small difference
between the active and inactive states of FGFR tyrosine
kinase domains (Mohammadi et al. 1996), we suspect
that other FGFR3 missense mutations (e.g., Lys650Thr)
will be found to cause mild forms of disproportionate
and short stature. On the basis of our findings, we be-
lieve that FGFR3-mutation analysis is an appropriate
study for all patients with short stature, disproportion-
ate limbs, and any radiological changes consistent with
hypochondroplasia. Furthermore, it seems likely that
some FGFR3 polymorphisms may also play a role in
the multifactorial genetic determination of adult height.
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